Salouti et al., 2011 - Google Patents
Breast Cancer: Radioimmunoscintigraphy and RadioimmunotherapySalouti et al., 2011
View PDF- Document ID
- 9245058446261467819
- Author
- Salouti M
- Heidari Z
- Publication year
- Publication venue
- 12 Chapters on Nuclear Medicine
External Links
Snippet
Breast cancer is one of the most common diseases and a major public health problem in the world today. It is responsible for 32% of all cancers and 15% of cancer deaths in women (Dirisamer et al., 2010). Advances in diagnosis and treatment of breast cancer have led to …
- 206010006187 Breast cancer 0 title abstract description 96
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Van de Watering et al. | Zirconium‐89 labeled antibodies: a new tool for molecular imaging in cancer patients | |
| US11427648B2 (en) | Anti-CD146 antibodies and uses thereof | |
| JP5110768B2 (en) | Monoclonal antibody PAM4 and its use for diagnosis and treatment of pancreatic cancer | |
| CN1675245B (en) | Humanized monoclonal antibody hPAM4 | |
| US7781568B2 (en) | Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer | |
| Navarro-Teulon et al. | General overview of radioimmunotherapy of solid tumors | |
| Spiegelberg et al. | CD44v6‐Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody‐Based Approaches | |
| Reddy et al. | Immuno-positron emission tomography in cancer models | |
| Wei et al. | Engineered antibodies as cancer radiotheranostics | |
| Dijkers et al. | Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy | |
| Salsano et al. | PET imaging using radiolabelled antibodies: future direction in tumor diagnosis and correlate applications | |
| Wållberg et al. | Design and evaluation of radiolabeled tracers for tumor imaging | |
| Niu et al. | Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression | |
| JP2017214308A (en) | Radioactive pharmaceutical composition, and radiolabeled antibody screening method | |
| McQuarrie et al. | The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients | |
| Salouti et al. | Breast Cancer: Radioimmunoscintigraphy and Radioimmunotherapy | |
| Altıparmak Güleç et al. | Radiopharmaceuticals developed for 89Zr-Immuno-PET | |
| Heidari et al. | Targeting molecular imaging of breast cancer by radioimmunodetection method in nuclear medicine | |
| Kim et al. | Preclinical application of radioimmunoguided surgery using anti-carcinoembryonic antigen biparatopic antibody in the colon cancer | |
| Movahed et al. | Radiolabeled HER2-targeted molecular probes in breast cancer imaging: current knowledge and future prospective | |
| Kairemo et al. | Radioimmunodetection of malignant solid tumours | |
| BARRON | LAMK M. LAMKI | |
| Ku | Theranostic Implications of Molecular Imaging in Cancer | |
| Perk et al. | Immuno-Positron Emission | |
| Chen et al. | Advancements in colorectal cancer detection: The role of immuno‐positron emission tomography, immuno‐single‐photon emission computed tomography, and machine learning applications |